RVMD实时信号 | 通过Getagraph.com最大化利润

购买 3707 min ago

@ $35.97

发出时间: 27 Apr 2024 @ 02:23

回报率: -0.03%

上一信号: Apr 27 - 01:09

上一信号: 出售

回报率: -0.72 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):
Our systems believe the stock currently is undervalued by 0.09% compare to its pairs and should correct upwards.

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers...

Stats
今日成交量	1.20M
平均成交量	1.46M
市值	5.92B
EPS	$0 ( 2024-02-26 )
下一个收益日期	( $0 ) 2024-05-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-9.32
ATR14	$1.710 (4.76%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-10	Goldsmith Mark A	Sell	7 500	Common Stock
2024-04-10	Goldsmith Mark A	Sell	5 000	Common Stock
2024-04-10	Goldsmith Mark A	Sell	5 000	Common Stock
2024-04-10	Patel Sushil	Sell	2 155	Stock Option (Right to Buy)
2024-04-10	Patel Sushil	Buy	2 155	Common Stock

INSIDER POWER
73.03
Last 99 transactions
Buy: 5 403 428 \| Sell: 788 601

相关性 (AI algo v.1.1b): Undervalued: 0.09% $35.99 paired level. (算法实时跟踪最相关股票的变化并提供即时更新)

音量相关性

長: -0.58 (weak negative)

短: -0.67 (moderate negative)

Signal:(50) Neutral

Revolution Medicines Inc 相关性

10 最正相关
TBNK	0.884
RING	0.853
RGLD	0.852
DOOO	0.849
GTH	0.834
GRAB	0.834
TRUE	0.831
PWOD	0.83
MCHI	0.828
YY	0.825

10 最负相关
LLNW	-0.82
SFET	-0.808
LNSR	-0.801

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Revolution Medicines Inc 相关性 - 货币/商品

0.21
( neutral )

-0.34
( neutral )

0.00
( neutral )

0.01
( neutral )

-0.25
( neutral )

-0.10
( neutral )

Revolution Medicines Inc 财务报表

Annual	2023
营收:	$11.58M
毛利润:	$2.27M (19.61 %)
EPS:	$-3.86

FY	2023
营收:	$11.58M
毛利润:	$2.27M (19.61 %)
EPS:	$-3.86

FY	2022
营收:	$35.38M
毛利润:	$25.72M (72.71 %)
EPS:	$-3.08

FY	2021
营收:	$29.39M
毛利润:	$29.39M (100.00 %)
EPS:	$-2.57

Financial Reports:

No articles found.

Revolution Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.